National News

Updated Price Concessions – July 2019

NPA News - 19 July 2019 - 4:48pm
  Drug (pack size) Price concession Alverine  capsules 60mg (100) (NEW) £9.80 Betahistine  tablets 8mg (84) £1.37 Betahistine tablets 16mg (84) £2.50 Bumetanide  tablets 1mg (28) (NEW) £1.65 Cefalexin oral suspension 250mg/5ml  (100ml) (NEW) £1.95 Celecoxib  capsules 200mg (30) (NEW) £9.43 Diamorphine  powder for solution for injection ampoules 10mg (5) (NEW) £16.56 Diamorphine  powder for solution for injection ampoules 30mg (5) (NEW) £16.52 Escitalopram  tablets 20mg (28) (NEW) £5.54 Finasteride tablets  5mg (28) (NEW) £1.79 Hydroxychloroquine tablets 200mg (60) (NEW) £5.99 Ibandronic Acid tablets 150mg (28) £9.95 Losartan  tablets 12.5mg (28) £3.82 Metoprolol  tablets 50mg (28) (NEW) £5.08 Metoprolol  tablets 100mg (28) (NEW) £4.00 Naproxen  gastro-resistant tablets 250mg (56) (NEW) £9.95 Nebivolol  tablets 5mg (28) (NEW) £5.00 Pantoprazole  gastro-resistant tablets 20mg (28) (NEW) £3.65 Pantoprazole tablets gastro-resistant 40mg (28) £3.85 Prednisolone  tablets 5mg (28) £2.25 Prednisolone sodium phosphate  ear/eye drops 0.5% (10ml) £2.49 Quetiapine  tablets 200mg (60) (NEW) £9.00 Quinine sulphate  tablets 200mg (28) (NEW) £1.77 Quinine sulphate tablets 300mg (28) (NEW) £5.52 Risedronate sodium tablets 35mg (4)   £11.68 Tamoxifen tablets 20mg (30) £3.40 Tolbutamide tablets 500mg (28) £17.25 Topiramate  tablets 50mg (60) (NEW) £11.49 Valsartan 160mg / Hydrochlorothiazide 12.5mg tablets (28) £8.90 Valsartan capsules 160mg (28) £14.99  …
Categories: National News

Serious Shortage Protocols (SSPs) webinar now on-demand

PSNC News - 19 July 2019 - 4:43pm

Community pharmacy contractors can now access an online recording of PSNC a recent Serious Shortage Protocols (SSPs) webinar.

Over 600 people registered for yesterday’s webinar presented by Gordon Hockey (PSNC Director of Operations and Support) and Suraj Shah (PSNC Drug Tariff and Reimbursement Manager).

During the webinar, Gordon explained what an SSP is, clarified situations when they may be used, described what they may involve, and talked through the decisions you may need to make when one is in place. PSNC Drug Tariff and Reimbursement Manager, Suraj Shah, was also on hand to explain the endorsement and claiming process.

So, if you want to better understand SSPs, watching this webinar is a useful opportunity to get to grips with the legislation before it is used.

Click here to view an on-demand version of the webinar.*

You can also click here to view the slide pack used in the webinar.

*Please note, to watch the recording, you will need to register (or input the email address you registered with previously).

 

Categories: National News

July 2019 Price Concessions – 2nd update

PSNC News - 19 July 2019 - 4:00pm

Department of Health and Social Care (DHSC) has today granted the following list of price concessions:

Drug Pack size Price Concession Alverine 60mg capsules 100 £9.80 Bumetanide 1mg tablets 28 £1.65 Cefalexin 250mg/5ml oral suspension 100ml £1.95 Celecoxib 200mg capsules 30 £9.43 Diamorphine 10mg powder for solution for injection ampoules 5 £16.56 Diamorphine 30mg powder for solution for injection ampoules 5 £16.52 Escitalopram 20mg tablets 28 £5.54 Finasteride 5mg tablets 28 £1.79 Hydroxychloroquine 200mg tablets 60 £5.99 Metoprolol 50mg tablets 28 £5.08 Metoprolol 100mg tablets 28 £4.00 Naproxen 250mg gastro-resistant tablets 56 £9.95 Nebivolol 5mg tablets 28 £5.00 Pantoprazole 20mg gastro-resistant tablets 28 £3.65 Quetiapine 200mg tablets 60 £9.00 Quinine sulfate 200mg tablets 28 £1.77 Quinine sulfate 300mg tablets 28 £5.52 Topiramate 50mg tablets 60 £11.49

DHSC previously (15.07.2019) granted the following price concessions:

Drug Pack size Price Concession Betahistine 8mg tablets 84 £1.37 Betahistine 16mg tablets 84 £2.50 Ibandronic acid 150mg tablets 1 £9.95 Losartan 12.5mg tablets 28 £3.82 Pantoprazole 40mg gastro-resistant tablets 28 £3.85 Prednisolone 5mg tablets 28 £2.25 Prednisolone sodium phosphate 0.5% ear/eye drops 10ml £2.49 Risedronate sodium 35mg tablets 4 £11.68 Tamoxifen 20mg tablets 30 £3.40 Tolbutamide 500mg tablets 28 £17.25 Valsartan 160mg / Hydrochlorothiazide 12.5mg tablets 28 £8.90 Valsartan 160mg capsules 28 £14.99

No additional endorsements are required for price concessions. A price concession only applies for the month in which it is granted.

PSNC is still working with the DHSC to agree further concessionary prices on other drugs reported to be unavailable at the stated July 2019 Drug Tariff price. Contractors will be alerted to further updates to the price concession list through our website and via our e-news email.  If you wish to subscribe to our email list, you can receive an email as soon as any announcements are made. Please note that PSNC cannot provide details of any generic products awaiting price concession approval from DHSC.

If you have problems obtaining a Part VIII product or problems obtaining the product at the stated Drug Tariff price, please report the issue to PSNC using the online feedback form on the PSNC Website.
Please include full details of the supplier and price paid for any products sourced above the Drug Tariff price. PSNC will investigate the extent of the problem and if appropriate discuss the issue with DHSC.

Categories: National News

Supply Issue Notice: Sanofi Experience Distribution Disruptions

PSNC News - 19 July 2019 - 3:53pm

Sanofi are currently experiencing difficulties ensuring sufficient product availability for normal supply to pharmacies. Sanofi say ‘The problem was caused by a change in our UK logistics provider and an unexpected technical issue with one of their IT systems.’

Sanofi expect product availability will be back to normal within two weeks and ask that pharmacy teams ‘only order the minimum amount of stock that you need during this period’.

Please note Sanofi Pasteur vaccines are not affected as these products are distributed by Movianto.

For order-related queries please contact AAH or Phoenix.

Sanofi’s letter to pharmacy teams can be found here.

 

 

Categories: National News

MHRA Drug Safety Update July 2019

PSNC News - 18 July 2019 - 3:50pm

Date issued: 17th July 2019

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 12 Issue 12 July 2019) has been published and includes articles on:

  • Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease
  • Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation
  • Rivaroxaban (Xarelto▼): reminder that 15 mg and 20 mg tablets should be taken with food
  • Letters and drug alerts sent to healthcare professionals in June 2019
  • Medical Device Alerts issued in June 2019

To see the latest MHRA Drug Safety Update in full, visit the GOV.uk website.

Categories: National News

Flu Vaccination Service: An update on vaccine supply

PSNC News - 18 July 2019 - 2:20pm

Public Health England, NHS England and NHS Improvement have issued a letter to general practices and community pharmacy contractors regarding the supply of quadrivalent flu vaccines. Manufacturers of quadrivalent flu vaccines have informed them that the delayed World Health Organization recommendation on vaccine strain has had an impact on their vaccine supply.

Sanofi Pasteur has indicated they plan to phase some of the deliveries of the inactivated quadrivalent influenza vaccines for those at risk and under 65 years, with some vaccines being delivered by the end of November 2019.

Contractors are therefore advised, if they have placed an order for quadrivalent influenza vaccines, to contact the relevant manufacturer or supplier to confirm delivery dates in order to plan effectively for the season.

Click here to view the letter

Categories: National News

2020 Early May Bank Holiday change affects pharmacy opening requirements

PSNC News - 16 July 2019 - 2:00pm

The Government announced last month that it is pushing back next year’s Early May Bank Holiday by a few days to Friday 8th May 2020. The move has been made to coincide with the 75th anniversary of the Victory in Europe (VE) Day, which formally marked the end of World War II.

Community pharmacies do not have to open on days which are specifically mentioned in the Regulations or a day which has been specifically designated as a ‘bank holiday’ (such as 8th May 2020), unless directed to open by their local NHS England team. On those days, the hours that the pharmacy would ordinarily have been open will be treated as having been open for the purpose of counting the core contractual hours that week (i.e. there is no requirement to make up those hours on other days).

In practice this means that next year community pharmacies must open on 4th May 2020 for their usual Monday opening hours, but are permitted to be closed on Friday 8th May without giving notice or applying to change their core hours.

Other days in 2020 when all NHS community pharmacies in England will not be required to open (unless otherwise directed by their local NHS England team) are as follows:

  • New Year’s Day (1st January 2020)
  • Good Friday (10th April 2020)
  • Easter Sunday (12th April 2020)
  • Easter Monday (13th April 2020)
  • Early May Bank Holiday/ Victory in Europe Day (8th May 2020)
  • Spring Bank Holiday (25th May 2020)
  • Summer Bank Holiday (31st August 2020)
  • Christmas Day (25th December 2020)
  • Boxing Day* (28th December 2020)

*If a bank holiday falls on a weekend, a ‘substitute’ weekday becomes the bank holiday, usually the following Monday. In 2020, Boxing Day is a Saturday so the designated bank holiday is Monday 28th December 2020. This means that any pharmacy that normally opens on a Saturday would still have to open as usual on Boxing Day, unless they have been granted permission to close by their local NHS England team.

PSNC’s annual opening hours factsheet provides contractors with a quick reference guide on which public and bank holidays pharmacies can close without giving notice. Our 2020 factsheet has just been published:

Pharmacy opening hours factsheet (2020)

Categories: National News

Contract Factsheet – Pharmacy opening hours in 2020

PSNC News - 16 July 2019 - 1:51pm

PSNC’s Regulations and Support Team are often asked questions about the requirements in the terms of service relating to opening hours. This briefing contains a quick reference guide for 2020.

PSNC Briefing 025/19: Contract Factsheet – Pharmacy opening hours in 2020 (July 2019)

If you have queries on this PSNC Briefing or you require more information please contact William Goh, Regulations Officer.

To browse other PSNC briefings on Contract & IT, click here.

View Article…

Categories: National News

Shortage Notice: Nardil (phenelzine sulfate) 15mg tablets

PSNC News - 15 July 2019 - 4:49pm

Kyowa Kirin, the sole manufacturers of Nardil (phenelzine sulfate) 15mg tablets, are currently experiencing temporary disruptions.

Kyowa Kirin, the main supplier of Nardil (phenelzine sulfate) 15mg tablets have advised a resupply date of end of October 2019

Supplies are available from specialist importers on an ‘unlicensed’ basis. Ensure that where a prescriber wishes you to dispense an import, prescriptions are annotated ‘specials/unlicensed’ and are endorsed as follows:

  • Amount dispensed over pack size used;
  • Invoice price per pack size from which the order was supplied less any discount or rebate;
  • Manufacturers’/importers’ MHRA licence number;
  • Batch number of the product supplied;
  • SP

More information and details of alternative products can be found here on the SPS website.

Categories: National News

Shortage Notice: Salbutamol 2mg/5ml syrup

PSNC News - 15 July 2019 - 4:31pm

GlaxoSmithKline (GSK) and Pinewood, the manufacturers of Salbutamol 2mg/5ml syrup, are currently experiencing temporary disruptions.

GSK, the main supplier of Salbutamol 2mg/5ml syrup (Ventolin) have advised a resupply date of early August 2019

Pinewood are long term out of stock due to manufacturing issues and  are currently unable to advise a resupply date.  

Supplies are available from specialist importers on an ‘unlicensed’ basis. Ensure that where a prescriber wishes you to dispense an import, prescriptions are annotated ‘specials/unlicensed’ and are endorsed as follows:

  • Amount dispensed over pack size used;
  • Invoice price per pack size from which the order was supplied less any discount or rebate;
  • Manufacturers’/importers’ MHRA licence number;
  • Batch number of the product supplied;
  • SP

More information and details of alternative products can be found here on the SPS website.

Categories: National News

July 2019 Price Concessions – 1st update

PSNC News - 15 July 2019 - 4:00pm

Department of Health and Social Care (DHSC) has today granted the following initial list of price concessions:

Drug Pack size Price Concession Betahistine 8mg tablets 84 £1.37 Betahistine 16mg tablets 84 £2.50 Ibandronic acid 150mg tablets 1 £9.95 Losartan 12.5mg tablets 28 £3.82 Pantoprazole 40mg gastro-resistant tablets 28 £3.85 Prednisolone 5mg tablets 28 £2.25 Prednisolone sodium phosphate 0.5% ear/eye drops 10ml £2.49 Risedronate sodium 35mg tablets 4 £11.68 Tamoxifen 20mg tablets 30 £3.40 Tolbutamide 500mg tablets 28 £17.25 Valsartan 160mg / Hydrochlorothiazide 12.5mg tablets 28 £8.90 Valsartan 160mg capsules 28 £14.99

No additional endorsements are required for price concessions. A price concession only applies for the month in which it is granted.

PSNC is still working with the DHSC to agree further concessionary prices on other drugs reported to be unavailable at the stated June 2019 Drug Tariff price. Contractors will be alerted to further updates to the price concession list through our website and via our e-news email.  If you wish to subscribe to our email list, you can receive an email as soon as any announcements are made. Please note that PSNC cannot provide details of any generic products awaiting price concession approval from DHSC.

If you have problems obtaining a Part VIII product or problems obtaining the product at the stated Drug Tariff price, please report the issue to PSNC using the online feedback form on the PSNC Website.
Please include full details of the supplier and price paid for any products sourced above the Drug Tariff price. PSNC will investigate the extent of the problem and if appropriate discuss the issue with DHSC.

Categories: National News

Contractor Announcement: Category M prices to increase from August

PSNC News - 15 July 2019 - 2:00pm

After discussions with PSNC, Category M reimbursement prices will increase by £15 million a month from August 2019, the Department of Health and Social Care (DHSC) has confirmed.

This is to correct a predicted shortfall in the margin delivery rate for the current financial year and it will be reviewed in the autumn.

At the same time, the Single Activity Fee (SAF) will rise by 1p to £1.27 per item from August to ensure delivery of the correct amount of funding to contractors this year.

The Category M price increases will help to ensure that the overall amount of margin delivered in this financial year is the agreed annual sum of £800m.

For the past year the margin delivery rate has had to be set lower than £800m as DHSC sought to recover sums owing from the over-delivery of margin in previous years.

Although Category M prices increased in April 2019, April reimbursement levels were lower than anticipated.  This appears to have been driven by movement in the drug mix in April, which means that contractors have not seen the positive cash flow impact that would have been expected.

The margin recovery process has affected contractors’ cashflow and PSNC remains very concerned about the difficult financial position many contractors find themselves in. PSNC has highlighted this to DHSC and NHS England & Improvement and we will continue to work with them to try to smooth the delivery of margin to contractors going forwards.

The August price increases should bring at least some relief to contractors, but we will continue to monitor delivery of margin and to press for improvements to funding delivery to try to avoid similar cashflow issues recurring in the future.

Simon Dukes, PSNC Chief Executive, said:

“The past few months have been incredibly difficult for many community pharmacy contractors, and this has in part been caused by the need to keep Category M reimbursement prices low following excess margins earned in previous financial years. These August price increases are being made to try to correct margin delivery for this financial year and this should bring some relief for contractors.

PSNC is very concerned about the impact that cashflow difficulties are having on pharmacies and we have made this very clear to DHSC. We are pressing for improvements to the funding and margin distribution systems to try to avoid this sort of scenario in the future. However, within the current funding structures and with wider negotiations on funding ongoing, the Committee felt that an immediate increase in Category M reimbursement prices was the best course of action to ensure that contractors receive all the funding to which they are entitled this year.”

Categories: National News

PSNC appoints Sue Killen as new chair

PSNC News - 15 July 2019 - 11:02am

Sue Killen has been appointed as non-executive Chair of PSNC.

Sue brings a wealth of experience from working in government and the third sector and will take up the post at PSNC on 1st September 2019. She replaces Sir Michael Pitt who will complete four years as Chair at the end of August.

Sue previously worked as Chief Executive of first-aid charity St John Ambulance for ten years and she is also a former interim Chief Executive and registrar of the Nursing and Midwifery Council. She is currently Vice Chair of the UK’s largest social housing association, Clarion; Chair of its charitable foundation and Chair of the Katie Piper Foundation.

Sue was formerly a Director General in the Civil Service. During a long Civil Service career she worked in a wide range of roles including leading an independent review of children’s palliative care and tackling the impact of drug misuse. She has held a range of Non-Executive Director and Trustee roles over the last 20 years.

Sue’s role at PSNC will include chairing all PSNC meetings; overseeing the governance of PSNC and championing and building strategic support for community pharmacy.

Sue Killen said:

“I am delighted to take on this role at such an important time for the future of community pharmacy. I know from my previous roles what an essential role pharmacists play in community health. I believe strongly that the NHS Long Term Plan provides an opportunity to develop this further and to secure greater recognition for the vital role community pharmacists play.”

PSNC Chief Executive, Simon Dukes, said:

“It is a pleasure to welcome Sue Killen to PSNC and we are looking forward to drawing on her wealth of experience and skills to help us in our work. Sue will undoubtedly prove a key asset as we work to promote community pharmacy to policy makers and to guide the sector through the potentially radical changes ahead. We would also like to thank Sir Mike Pitt for all his work on behalf of PSNC and community pharmacies over the past four years, helping to steer the Committee through some particularly challenging times.”

Categories: National News

CPPE Corner: Leadership – Building on your Mary Seacole award

PSNC News - 11 July 2019 - 5:01pm

The Centre for Pharmacy Postgraduate Education (CPPE) will be running leadership workshops for those who have already completed the Mary Seacole programme, and want to build further on their skills. Here we find out more about the workshops.

Have you successfully completed the Mary Seacole programme for community pharmacy and are looking to continue to develop your leadership skills?

CPPE has developed a series of two short workshops to support you in taking your leadership skills to the next level.

The workshops will give you an opportunity to explore how you have developed as a leader and how your new-found knowledge and skills have helped you to improve your practice.

There will also be plenty of opportunities for personal reflection, experimentation and feedback, which will enable you to understand yourself even better.

After completing the workshop, you will be able to apply the Self-Directed Learning Model to help you to continue your leadership journey, use the GROWS model to coach a team member or peer and reflect on your leadership success and identify how you have applied leadership skills gained on the Mary Seacole programme.

You will also be able to undertake a peer discussion, which you can use towards your revalidation.

These workshops are available in the following areas:

South West, Holiday Inn, Taunton Deane

  • Workshop 1 – 21 September 2019, 10:00-1:00pm
  • Workshop 2 – 9 November 2019, 10:00am-1:00pm

Manchester, Holiday Inn Express, Leigh Sports Village

  • Workshop 1 – 13 October 2019, 10:00am-1:00pm
  • Workshop 2 – 24 November 2019, 10:00am-1:00pm

Birmingham, Hallmark Hotel, Hagley Road

  • Workshop 1 – 12 January 2020, 10:00am-1:00pm
  • Workshop 2 – 1 March 2020, 10:00am-1:00pm

Newcastle, Copthorne Hotel

  • Workshop 1 – 19 January 2020, 10:00am-1:00pm
  • Workshop 2 – 1 March 2020, 10:00am-1:00pm

London, the Montague on the Gardens Hotel

  • Workshop 1 – 14 January 2020, 10:00am-1:00pm
  • Workshop 2 – 17 March 2020, 10:00am-1:00pm

Please note that you will be required to attend both workshops 1 and 2 in the area you choose.

For more information about the workshops and to choose an event, visit the CPPE website.

Categories: National News

Contractor notification: Melatonin oral solution – retrospective price adjustment

PSNC News - 11 July 2019 - 3:30pm

Following representation from PSNC the Department of Health and Social Care (DHSC) have retrospectively determined that from July 2019:

  • Melatonin 1mg/1ml oral solution sugar free (150ml) – is added to Part VIIIA of the Drug Tariff as a Category C line based on Colonis Pharma,
  • Melatonin 5mg/5ml oral solution and Melatonin 5mg/5ml oral suspension – are deleted from Part VIIIB.

Please note that payment for July’s prescriptions will reflect the above retrospective determination; not as per the published July Drug Tariff.

For more information on Melatonin 1mg/1ml oral solution sugar free see the product information leaflet here or contact Colonis: Email: medinfo@colonis.co.uk or Telephone: 01892 739 403.

FAQs

Q. I have received a prescription for ‘Melatonin 5mg/5ml oral solution sugar free x 150ml’ and have dispensed the licensed ‘Melatonin 1mg/1ml oral solution sugar free x 150ml’ as per MHRA guidelines, what will I be paid for?

A. All prescriptions for ‘Melatonin 5mg/5ml oral solution sugar free’ submitted in July’s prescription bundle, will be reimbursed the dm+d list price for ‘Melatonin 1mg/1ml oral solution sugar free’ which is currently £130.00 for a pack of 150ml manufactured by Colonis Pharma Ltd.

Q. I have received a prescription for ‘Melatonin 5mg/5ml oral suspension sugar free x 150ml’ and have dispensed the licensed ‘Melatonin 1mg/1ml oral solution sugar free x 150ml’ as per MHRA guidelines, what will I be paid for?

A. If the pharmacy team has endorsed ‘Melatonin 1mg/1ml oral solution sugar free x 150m, Colonis Pharma Ltdl’, they will be paid based on the dm+d list price of £130.00. If the prescription has not been endorsed, it will be referred back to the pharmacy for clarification.

Categories: National News

Class 4 Drug Alert: Caution in Use – Emerade solution for injection pre-filled syringe 150mcg, 300mcg and 500mcg

NPA News - 11 July 2019 - 2:05pm
Ref: EL (19)A/17 11 July 2019 Emerade® solution for injection pre-filled syringe 150mcg, 300mcg and 500mcg. Manufactured by Pharmaswiss Česka republika s.r.o. (an affiliate of Bausch & Lomb UK Limited) Product Product Licence (PL) number Emerade® solution for injection in pre-filled syringe 150 micrograms PL 33616/0013 Emerade®solution for injection in pre-filled syringe 300 micrograms PL 33616/0014 Emerade® solution for injection in pre-filled syringe 500 micrograms PL 33616/0015 Bausch & Lomb UK limited has identified a risk of certain units of Emerade® device in all strengths failing to deliver a dose of adrenaline from the syringe due to blockage of the needle. Healthcare professionals, including pharmacists, are advised to contact all patients/carers, who have been supplied with an Emerade® device to inform them of the potential defect and reinforce the recommendation to carry two in-date adrenaline auto-injectors with them at all times. The MHRA is not recalling batches of Emerade®. Further information can be found on the MHRA section on the GOV.UK website.…
Categories: National News

Class 4 MHRA drug alert – Emerade 150/300/500 micrograms solution for injection in pre-filled syringe

PSNC News - 11 July 2019 - 11:40am

July 11, 2019

Class 4 MHRA drug alert – Emerade 150/300/500 micrograms solution for injection in pre-filled syringe (Bausch & Lomb)

Drug alert number: EL (19)A/17

Date issued: 11th July 2019

The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 pharmacy level caution in use for:

Emerade 150 micrograms solution for injection in pre-filled syringe (Bausch & Lomb)

Emerade 300 micrograms solution for injection in pre-filled syringe (Bausch & Lomb)

Emerade 500 micrograms solution for injection in pre-filled syringe (Bausch & Lomb)

Bausch & Lomb UK limited has informed MHRA of a risk of Emerade products failing to deliver a dose of adrenaline from the syringe due to blockage of the needle.This issue was first detected in June 2018 during routine stability testing of the syringe component of Emerade, with potential to affect 1.5 in every ten thousand pens, and therefore considered a rare event. However, recent information indicates that the potential occurrence of needle blockage in batches on the market is higher than first estimated and we are therefore bringing it to the attention of patients. The potential for units on the market to have a blockage of the needle which could lead to Emerade failing to deliver a dose when activated is now estimated to be 0.23 %*, which would affect 2.3 in every thousand pens. However, if the patient follows the existing advice to carry two in-date pens with them at all times, the risk of not being able to deliver a dose of adrenaline before the emergency services arrive is substantially reduced (from 0.23% to 0.000529%).

Advice for community pharmacy teams:

Healthcare Professionals should contact all patients, and their carers, who have been supplied with an Emerade device to inform them of the potential defect and reinforce the advice to always carry two in-date adrenaline auto-injectors with them at all times.

For stock enquiries please contact Bausch & Lomb Customer Services, Tel: 0208 781 2991, Email: Pharma_CS@bausch.com

For medical information enquiries please contact Lizanne Kombrink (Pharmacovigilance and Medical Information Officer), Tel: 0208 781 5523, Email: Pharmacovigilance.UK@bausch.com

PL number: PL 33616/0013, PL 33616/0014, PL 33616/0015

To view the alert please visit the GOV.uk website.

Categories: National News

Diabetes in Healthcare – free online training from Diabetes UK

PSNC News - 10 July 2019 - 9:23am

Diabetes UK has launched a free online training programme aimed at healthcare professionals who do not work in a diabetes specialist area, which is suitable for pharmacy professionals.

The programme consists of an introduction and seven distinct modules covering diabetes diagnosis, treatment, monitoring and more. It is followed by an assessment and certificate upon completion. It is estimated to take around two and a half hours to complete.

In order to access the training, you will need to register for an account with Diabetes UK which only takes a few minutes.

Click here to access the programme

Categories: National News

Common dispensing errors resulting in indemnity claims (UK)

NPA News - 9 July 2019 - 4:54pm
Dear Superintendent, I would like to highlight some commons types of dispensing errors in my update today which have resulted in significant indemnity claims against pharmacies. A number of the claims have involved monitored dosage systems (MDS). Example 1: dispensing patient returns A significant claim has arisen from an error involving patient-returned vials of heparin which were accidently re-dispensed to a pregnant patient. The patient had administered a few doses of heparin before realising that the vials had been used before, and alerted the pharmacy. The pharmacy accepted that the heparin vials were patient-returned medicines which had been accidently re-dispensed. Once the patient realised the error, she was treated with preventive medication against the potential risk of infections such as HIV and hepatitis B. The patient went on to give birth to a healthy baby. However, the experience allegedly resulted in a significant ongoing psychological impact on the patient, both during her remaining pregnancy and after.…
Categories: National News
Syndicate content
Continuing Professional Development Just visiting this site means you are probably performing CPD - record it online at www.uptodate.org.uk
Site developed by Gary Warner
Drupal theme by Kiwi Themes.